Compare Amylx Pharmaceuticals Inc (AMLX) vs Celsius Holdings, Inc. (CELH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Celsius Holdings, Inc. — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Celsius Holdings, Inc. trades at $30.7 (market cap $7.82B). The key difference: Celsius Holdings, Inc. is far larger — about 3.9× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Celsius Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| AMLX | CELH | |
|---|---|---|
Market Cap | $1.98B | $7.82B |
Sector | Health | Consumer Staples |
52-Week High | $18.70 | $64.86 |
52-Week Low | $7.64 | $27.75 |
Enterprise Value | $1.70B | $9.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Celsius Holdings (CELH) trades at $30.60, showing modest daily gains amid a broader bearish technical trend. The stock demonstrates strong fundamental growth with revenue surging from $654M in 2022 to $2.52B in 2025, though net margins compressed to 4.29%. Recent quarters consistently beat EPS estimates, and analyst sentiment remains overwhelmingly bullish with a $53.30 consensus target. However, negative cash flow trends and ongoing legal investigations present headwinds.
CELH offers significant upside potential based on analyst targets and robust revenue expansion, particularly in international markets. Key risks include margin pressure, high valuation multiples, and legal overhangs from shareholder investigations. The stock's investment case hinges on sustaining growth momentum while navigating competitive and operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Celsius Holdings, Inc.
Celsius Holdings Inc engages in the development, marketing, sale, and distribution of functional calorie-burning beverages. It offers flavors including cola, orange, wild berry and lemon iced tea and non-carbonated flavors such as Raspberry Acai Green Tea and Peach Mango Green Tea under the Celsius brand name. The company distributes its products through direct-store-delivery distributors, as well as directly to retailers across various retail segments, including supermarkets, convenience stores, drug stores, nutritional stores, mass merchants, health clubs, spas, gyms, military, and e-commerce websites.
Read more on CELH →
